Study details
Enrolling now
Empagliflozin Treatment in Kidney Transplant Recipients
VA Office of Research and Development
NCT IDNCT06013865ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
264
Study length
about 6 years
Ages
19+
Locations
5 sites in IA, IL, NE +2
What this study is about
Researchers are testing whether empagliflozin, a medication, can improve outcomes for kidney transplant recipients. The trial will last 2186 days and involve approximately 264 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Empagliflozin
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
empagliflozin (SGLT2 inhibitor; increases glucose excretion in urine)
Drug routes
oral (Oral Tablet)
Endpoints
Secondary: Blood Pressure, Body Weight, Death, Glycemic Control
Body systems
Renal